MedDataX Logo

Special Survey Long-term Treatment With Tiotropium on COPD

NCT ID: NCT00638183

Last Updated: 2014-06-19

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

385 participants

Study Classification

OBSERVATIONAL

Study Start Date

2005-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Since Spiriva Inhalation Capsules 18mcg (hereinafter this product) are indicated for treatment of patients with chronic obstructive pulmonary disease (i.e. patients with chronic bronchitis or pulmonary emphysema) and usually intended for long-term use, the present survey is conducted to collect safety and effectiveness information on the use of this product for long period of time in daily clinical settings, and to obtain proper drug use information.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Tiotropium in the Treatment of the Patients With Chronic Obstructive Pulmonary Disease

NCT02177318

Pulmonary Disease, Chronic Obstructive
COMPLETED

Safety and Effectiveness of Spiriva in COPD (Chronic Obstructive Pulmonary Disease) Patients Under the Real Condition of Usual Practice

NCT00624377

Pulmonary Disease, Chronic Obstructive
COMPLETED

Spiriva® in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT02172482

Pulmonary Disease, Chronic Obstructive
COMPLETED

Spiriva® in Patients With Chronic Obstructive Pulmonary Disease (COPD) in Daily Practice

NCT02172495

Pulmonary Disease, Chronic Obstructive
COMPLETED

Assessment of Chronic Obstructive Pulmonary Disease (COPD) Therapy From the Physicians Perspective Using Tiotropium as an Example

NCT01036763

Pulmonary Disease, Chronic Obstructive
COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Disease, Chronic Obstructive

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients of Chronic Obstructive Pulmonary Disease
2. Patients were expected to use the product for long period of time

Exclusion Criteria

1. Patients with glaucoma
2. Patients with micturition disorder due to prostatic hyperplasia etc.
3. Patients with a history of hypersensitivity to atropine or its derivatives or to any component of this product
Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Boehringer Ingelheim

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Boehringer Ingelheim

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Boehringer Ingelheim

Role: STUDY_CHAIR

Boehringer Ingelheim

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Boehringer Ingelheim Investigational Site

Asahikawa, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Chikushino-shi, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Daitō, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Ebina, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Echizen, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Fukui, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Fukushima, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Funabashi, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Gosen, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Habikino, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Hakodate, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Hayashimacho, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Higashiosakaka, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Himeji, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Hirosaki, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Hiroshima, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Hitachi, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Iizuka, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Ikoma, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Ishinomaki, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Itanocho, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Kasukabe, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Katsuragichō, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Kawasaki, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Kishiwada, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Kitakyushu, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Kobayashi, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Koga, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Komaki, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Komatsu, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Kōshū, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Kumamoto, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Kunimichō, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Kyoto, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Kyōtango, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Matsudo, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Matsue, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Matsumoto, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Mihamacho, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Minamiuonuma, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Mishima, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Mizumakimachi, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Morioka, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Nagaoka, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Nagasaki, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Nagoya, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Nichinan, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Niihama, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Nōgata, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Numata, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Obihiro, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Odawara, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Osaka, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Ōbu, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Ōgaki, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Ōkuchi, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Ōtsu, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Saiki, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Saitama, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Sakai, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Sakede, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Sapporo, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Sayama, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Sendai, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Shiroishi, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Shiroishichō, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Shizuoka, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Tagawa, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Takarazuka, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Tokyo Chiyoda-ku, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Tokyo Higashiyamato, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Tokyo Itabashi-ku, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Tokyo Kita-ku, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Tokyo Koto-ku, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Tokyo Meguro-ku, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Tokyo Otaku-ku, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Tokyo Shinjuku-ku, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Tsu, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Tsukuba, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Ube, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Uji, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Urayasu, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Uruma, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Utsunomiya, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Yamagata, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Yame, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Yokohama, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Yorocho, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Yurihonjō, , Japan

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Japan

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

205.315

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Effect of Spiriva® on Health-related Quality of Life in Chronic Obstructive Pulmonary Disease (COPD) Patients Who Stopped Smoking During Treatment.
NCT02172547 COMPLETED
Spiriva® 18µg Once Daily in Chinese COPD Patients of Different Disease Severities
NCT00621582 COMPLETED
SPIRIVA in Ususal Care
NCT00274079 COMPLETED PHASE4
Measure of the Long Term Influence of SPIRIVA® in Acute Respiratory Disorders
NCT00274014 COMPLETED PHASE3
Observational Non-interventional Study With Spiriva in Chronic Obstructive Pulmonary Disease Patients With Exercise-induced Dyspnoea
NCT00540163 COMPLETED
Effect of Spiriva® 18 Microgram on Health-related Quality of Life and Physical Functioning in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Proven Hyperinflation
NCT02172521 COMPLETED
A Randomised, Double-blind, Placebo-controlled, 12 Week Trial to Evaluate the Effect of Tiotropium Inhalation Capsules (Spiriva) on the Magnitude of Exercise, Measured Using an Accelerometer, in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT00144326 COMPLETED PHASE3
Evaluation of the Long- Term Effects of Spiriva on Lung Function in COPD Patients
NCT00144339 COMPLETED PHASE3
Effect of Tiotropium Inhalation Capsules (Spiriva) on Exercise Tolerance in COPD Patients
NCT00157235 COMPLETED PHASE3
Bioequivalence Study of Tiotropium 18 μg Inhalation Powder, Hard Capsule With Spiriva®Handihaler® 18 μg Inhalation Powder, Hard Capsule in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT05986591 COMPLETED PHASE3
Effects of a 9-months Treatment of SPIRIVA on Health Related Quality of Life in Patients With COPD
NCT00274053 COMPLETED PHASE3
Spiriva (Tiotropium Bromide) Assessment of FEV1 - (SAFE-Portugal).
NCT00239408 COMPLETED PHASE4
Effect of Tiotropium (Spiriva) on Exercise Tolerance in COPD Patients
NCT00274508 COMPLETED PHASE3
Spiriva® Assessment of FEV1 (SAFE)
NCT00277264 COMPLETED PHASE3
Tiotropium 18ug Inhalation Capsule Using a Handihaler® Among Korean COPD Patients
NCT00620516 COMPLETED
Tiotropium Induced Bronchodilation in Lung CT Scored Emphysema
NCT00570544 COMPLETED
Effect of Spiriva on the Activities of Daily Living Score Recommended in Austrian COPD Guidelines
NCT00615992 COMPLETED
Bioequivalence Study of Tiotropium Bromide Inhalation Powder
NCT05161156 COMPLETED PHASE3
A Randomised, Double-blind, Crossover Study of Ba679BR Respimat in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT00292448 COMPLETED PHASE2
Tiotropium (Spiriva) Rehabilitation Study
NCT00274521 COMPLETED PHASE3
Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Inhalation Solution in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT03118765 COMPLETED PHASE2
Drug Use Survey of RESPIMAT in Patients With COPD
NCT01145053 COMPLETED
Long Term Safety and Tolerability of NVA237 Versus Tiotropium in Japanese Patients
NCT01119937 COMPLETED PHASE3
Tiotropium / Respimat One-Year Study
NCT00168831 COMPLETED PHASE3
Tiotropium / Respimat One Year Study in COPD.
NCT00387088 COMPLETED PHASE3